| Symbol | IMTX |
|---|---|
| Name | IMMATICS N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | PAUL-EHRLICH-STRAÿE 15, TUBINGEN, 72076, Germany |
| Telephone | +49 707153970 |
| Fax | — |
| — | |
| Website | https://www.immatics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001809196 |
| Description | Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The companys pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Immatics N.V. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000902664-26-002549 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G - Immatics N.V. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000947263-26-000045 <b>Size:</b> 7 KB
Read moreNew Form SCHEDULE 13G/A - Immatics N.V. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001493215-26-000108 <b>Size:</b> 10 KB
Read moreImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Read morePRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Read moreNew Form 3 - Immatics N.V. <b>Filed:</b> 2026-03-17 <b>AccNo:</b> 0001213900-26-029052 <b>Size:</b> 15 KB
Read moreImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Read more